Merck & Co., Inc. Business Acquisition, Pro Forma Net Income (Loss)
Merck & Co., Inc. (MRK) reported Business Acquisition, Pro Forma Net Income (Loss) of $4.64 billion for the 12-month period ending 2015-12-31, per its 10-K filed 2018-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2018-02-27
- Merck & Co., Inc. business acquisition, pro forma net income (loss) for the quarter ending 2015-12-31 was $995.00M, a 85.98% decline year-over-year.
- Merck & Co., Inc. business acquisition, pro forma net income (loss) for the quarter ending 2015-09-30 was $1.83B, a 160.74% increase year-over-year.
- Merck & Co., Inc. business acquisition, pro forma net income (loss) for the quarter ending 2015-06-30 was $764.00M, a 57.25% decline year-over-year.
- Merck & Co., Inc. business acquisition, pro forma net income (loss) for the quarter ending 2015-03-31 was $1.03B, a 23.73% decline year-over-year.
- Merck & Co., Inc. business acquisition, pro forma net income (loss) for fiscal 2015 was $4.64B, a 57.38% decline from fiscal 2014.
- Merck & Co., Inc. business acquisition, pro forma net income (loss) for fiscal 2014 was $10.89B.
- Merck & Co., Inc. business acquisition, pro forma net income (loss) for fiscal 2009 was $5.93B.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2015-12-31 | $995.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $2.83B derived: sum of 2 quarters · filed 2018-02-27 | $3.59B derived: sum of 3 quarters · filed 2018-02-27 | $4.64B 10-K · filed 2018-02-27 | |
| 2015-09-30 | $1.83B 10-Q · filed 2016-11-07 | $2.60B derived: sum of 2 quarters · filed 2016-11-07 | $3.65B 10-Q · filed 2016-11-07 | $10.73B derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | $764.00M 10-Q · filed 2016-08-08 | $1.81B 10-Q · filed 2016-08-08 | $8.90B derived: sum of 3 quarters · filed 2017-02-28 | $9.60B derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-03-31 | $1.03B 10-Q · filed 2016-05-09 | $1.02B 10-Q · filed 2015-05-07 | $8.13B derived: sum of 2 quarters · filed 2017-02-28 | $8.84B derived: sum of 3 quarters · filed 2017-02-28 | $10.62B derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $7.10B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $7.80B derived: sum of 2 quarters · filed 2017-02-28 | $9.59B derived: sum of 3 quarters · filed 2017-02-28 | $10.89B 10-K · filed 2017-02-28 | |
| 2014-09-30 | $703.00M 10-Q · filed 2015-11-05 | $2.49B derived: sum of 2 quarters · filed 2015-11-05 | $3.79B 10-Q · filed 2015-11-05 | ||
| 2014-06-30 | $1.79B 10-Q · filed 2015-08-06 | $3.09B 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | $1.36B 10-Q · filed 2015-05-07 | ||||
| 2009-12-31 | $5.93B 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |